Afzoline XL 10

Alfuzosin HCl

Functional symptoms of benign prostatic hyperplasia. Adjunctive treatment for vesical catheterization in acute urinary retention associated w/ benign prostatic hypertrophy.

10 mg once daily.

Should be taken with food: Take at the same time each day immediately after a meal. Swallow whole, do not crush/chew.

Hypersensitivity. Postural hypotension. Concurrent use w/ potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) or other α₁-blockers. Moderate or severe hepatic insufficiency (Child-Pugh class B or C). Severe kidney failure (CrCl <30 mL/min).

Discontinue in risk of new or worsening angina pectoris. Rule out prostate carcinoma prior to therapy. Postural hypotension especially in patients w/ history of symptomatic hypotension, who had hypotensive response to other medications or are receiving concurrent antihypertensives or nitrates. Acquired or congenital QT prolongation; intraoperative floppy iris syndrome during cataract surgery; priapism. Concomitant use w/ medications prolonging QT interval. Not recommended w/ other α-blockers. May affect ability to drive & use machines. Mild hepatic impairment. Severe renal impairment (CrCl <30 mL/min). Not indicated in women. Pregnancy. Childn.

Dizziness, fatigue, headache, pain; abdominal pain, constipation, dyspepsia, nausea; impotence; bronchitis, pharyngitis, sinusitis, URTI. TEN.

Increased risk of QT interval prolongation w/ mesoridazine, thioridazine, piperaquine, dronedarone, cisapride, pimozide, ziprasidone, bepridil, amifampridine, terfenadine, sparfloxacin, hydroxychloroquine, zuclopenthixol, fluoxetine, metronidazole, anagrelide, selected gonadotropin releasing hormone agonists, clozapine, escitalopram, moxifloxacin, dabrafenib, tizanidine, pasireotide, ivabradine, panobinostat, pitolisant, vinflunine, amiodarone, pimavanserin, tacrolimus, crizotinib, levofloxacin, quetiapine, aripiprazole, sevoflurane, delamanid, bedaquiline & QT interval prolonging drugs. Increased plasma conc w/ ketoconazole, atazanavir, fosamprenavir, saquinavir, itraconazole, ritonavir, nelfinavir, idelalisib, boceprevir, telaprevir, tipranavir, indinavir, cobicistat, diltiazem, cyclosporine, delavirdine, erythromycin, nefazodone, voriconazole, imatinib, amprenavir, quinupristin/dalfopristin, cimetidine. Increased exposure & risk of Torsades de Pointes w/ lopinavir/ritonavir, fluconazole, protriptyline, amoxapine, toremifene. Increased plasma conc & risk of QT interval prolongation w/ posaconazole, telithromycin, clarithromycin, salmeterol, granisetron, azithromycin, trimipramine, astemizole, perflutren lipid microsphere, chlorpromazine, dasatinib, clomipramine, gatifloxacin, trifluoperazine, flecainide, propafenone, vandetanib, ranolazine, mefloquine, telavancin, trazodone, domperidone, ciprofloxacin, Na phosphate, ondansetron, pazopanib, haloperidol, dofetilide, ofloxacin, lapatinib, asenapine, ibutilide, fingolimod, apomorphine, chloroquine, sorafenib, paliperidone, gemifloxacin, artemether/lumefantrine, tetrabenazine, nortriptyline, disopyramide, prochlorperazine, citalopram, procainamide, amitriptyline, desipramine, norfloxacin, quinine, quinidine, vemurafenib, imipramine, sunitinib, dolasetron, arsenic trioxide, promethazine, droperidol, solifenacin, iloperidone, halofantrine; nilotinib. Increased risk of serious & life-threatening reactions w/ darunavir. Increased risk of Torsade de Pointes w/ amisulpride, sulpiride & QT prolonging agents. Potentiated hypotensive effects w/ tadalafil; vardenafil, sildenafil, α₁-adrenergic blockers. Increased risk of QT interval prolongation & Torsades de Pointes w/ donepezil & QT prolonging agents. Increased exposure of CYP3A4 substrates w/ nilotinib & other CYP3A4 substrates prolonging QT interval. Exaggerated hypotension response w/ α₁- & β-adrenergic blockers. Increased risk of hypotension w/ avanafil. Reduced effectiveness w/ yohimbine, ma huang & α₁-adrenergic blockers.

Drugs for Bladder & Prostate Disorders

G04CA01 - alfuzosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.

D